Related Experiment Video
Updated: Jun 1, 2026
11:29
miRNA Expression Analyses in Prostate Cancer Clinical Tissues
Published on: September 8, 2015
A complex crosstalk between polymorphic microRNA target sites and AD prognosis
Bibekanand Mallick1, Zhumur Ghosh
1Wadsworth Center, New York State Department of Health, Albany, NY, USA.
RNA Biology
|June 11, 2011
Summary
Genetic variations, specifically single nucleotide polymorphisms (SNPs), disrupt microRNA (miRNA) regulation in Alzheimer's disease (AD). This study identifies key miRNA-SNP interactions, revealing their role in AD pathogenesis and aberrant gene expression.
Area of Science:
- Genomics
- Neuroscience
- Molecular Biology
Background:
- Genetic variations, including single nucleotide polymorphisms (SNPs), can alter microRNA (miRNA) binding sites, impacting gene regulation.
- Alzheimer's disease (AD) is a prevalent neurodegenerative disorder characterized by cognitive decline and associated genetic variations.
Purpose of the Study:
- To investigate how genetic variations (SNPs) interfere with miRNA-mediated gene regulation in Alzheimer's disease.
- To analyze the effect of these interactions on AD susceptibility and disease etiology.
Main Methods:
- Development of a computational pipeline to predict miRNA-target SNP interactions.
- Bioinformatic analysis to assess the functional impact (gain-of-function/loss-of-function) of miRNA networks in AD.
Main Results:
- Identified significant interactions between specific miRNAs (e.g., miR-214, miR-23a/b) and target SNPs in genes relevant to AD prognosis.
- Highlighted the contribution of synonymous mutations to AD pathogenesis.
- Demonstrated that miRNA-target variability is common in the adult brain, influencing gene expression in both normal and disease states.
Conclusions:
- Dysregulated miRNA networks, driven by miRNA-target SNP interactions, contribute to aberrant gene expression in Alzheimer's disease.
- These findings provide insights into molecular pathways of AD and potential therapeutic strategies involving miRNA-based interventions.
Related Concept Videos
01:22MicroRNAs
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
01:22MicroRNAs
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA ends...
01:22MicroRNAs
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA ends...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
02:23Abnormal Proliferation
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...